Boehringer Ingelheim, Lilly initiate EMPULSE study of Jardiance for acute heart failure
The EMPULSE study is a multi-centre, randomised, double-blind study to assess the oral EMPagliflozin 10mg compared to placebo
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Nov 19
The EMPULSE study is a multi-centre, randomised, double-blind study to assess the oral EMPagliflozin 10mg compared to placebo
11 Nov 19
Gazyva is a monoclonal antibody designed to attach to CD20, a protein that can be observed only on…
08 Nov 19
INXN-4001 makes use of non-viral delivery of a constitutively expressed multigenic plasmid to express human S100A1, SDF-1α, and…
08 Nov 19
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to promote erythropoiesis by increasing endogenous production of…
04 Nov 19
The results from EXCEED demonstrated a consistent and favourable safety profile for Cosentyx and no new safety signals…
30 Oct 19
The Phase III POSEIDON trial has reached a primary endpoint of statistically significant and clinically meaningful improvement in…
29 Oct 19
The clinical programme involves two studies, namely EAGLE-1, and EAGLE-2, and is conducted by the centres for disease…
15 Oct 19
Roche’s MabThera/Rituxan has secured the FDA approval in June 2018 and the European Commission approval in March 2019
14 Oct 19
JADE MONO-1 is a 12-week, double-blind, randomised parallel group study to evaluate abrocitinib 200mg, abrocitinib 100mg, or placebo
11 Oct 19
The FINCH Phase III programme has been designed to investigate the efficacy and safety of filgotinib, in early-stage…